Patients with cancer desire more communication about medical imaging risks, benefits
the ONA take:
According to a new study published online in the journal Radiology, researchers from Memorial Sloan Kettering Cancer Center in New York City, New York, have found that patients with cancer desire more information from health care professionals about medical imaging tests that use radiation.
For the study, researchers talked to 30 people who had undergone medical imagine exams to assess their understanding of the risks and benefits associated with different medical imaging procedures as well as what they expected health care professionals to communicate about those benefits and risks.
Results showed that most participants were highly aware of risks linked with ionizing radiation exposure, including the risk of future cancer; however, participants still wanted their own doctor to communicate this information to them.
Participants also reported wanting to be offered information about the reasons for certain testing and testing intervals, as well as alternative approaches. Those who sought more information turned to the Internet to answer their own questions.
The findings suggest that better communication about the benefits and risks of various medical imaging tests is needed as medical care becomes more patient-centered.
Patients with cancer desire more information from health care professionals about medical imaging tests that use radiation.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|